<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): JUNE 14, 2000
MOLECULAR BIOSYSTEMS, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
DELAWARE 1-10546 36-3078632
(STATE OF INCORPORATION) (COMMISSION FILE NUMBER) (I.R.S. IDENTIFICATION NO.)
10030 BARNES CANYON ROAD, SAN DIEGO, CALIFORNIA 92121
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)
REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE: (858) 812-7001
1
<PAGE>
Item 5. Other Events
MOLECULAR BIOSYSTEMS AND GENTA ANNOUNCE LICENSING DEAL FOR KEY ANTISENSE
TECHNOLOGY
On June 5, 2000, Molecular Biosystems, Inc. and Genta Incorporated announced the
licensing of a broad portfolio of patents and technology that relate to
antisense for therapeutic and diagnostic applications. The agreement includes
grants of both exclusive and non-exclusive rights to Genta from MBI on a
royalty-free basis in return for cash and shares of Genta common stock.
Item 7. Financial Statements and Exhibits
10.1 Press release dated June 5, 2000
10.2 License agreement between Molecular Biosystems, Inc. and Genta
Inc.
2
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
MOLECULAR BIOSYSTEMS, INC.
/s/ BOBBA VENKATADRI
-------------------------------
Bobba Venkatadri
President and Chief Executive Officer
6/13/00
-------------------------------
Date
3
<PAGE>
EXHIBIT INDEX
Exhibit Description
10.1 Press release dated June 5, 2000
10.2 License agreement between Molecular Biosystems, Inc. and Genta
Inc.
4
